Before the autoimmune disease was diagnosed, Teresa Kariuki had lost her legs to it. She thought she would die but she lived ...

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus.

Biogen’s new drug felzartamab is being tested to treat antibody-mediated rejection, a condition that happens when a kidney transplant patient’s immune system turns on the new organ and attacks it as ...

Novartis (NVS) has terminated a mid-stage trial for its oral Factor B inhibitor Fabhalta (iptacopan) in lupus nephritis, an inflammatory condition affecting the kidneys, because of strategic ...

Novartis has ended a mid-stage trial of Fabhalta for lupus nephritis, citing strategic considerations. The clinical-trial registry offered no further explanation and did not indicate whether safety or ...

Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta ​in patients with a serious ‌kidney ...

Background SLE is a complex autoimmune condition requiring evaluation across disease activity, permanent damage and ...

Judge Dianne Jones of Dallas County Court on Friday affirmed the July verdict of $604,025,000 handed down in July against C.H. Robinson (NASDAQ: CHRW) as a result of a fatal accident that killed three ...

The hope with CAR T cell therapies for autoimmune disease is that they can reset the immune system and induce deep remission. But recent trial pauses have renewed concerns about safety, patient ...

Absence of branched N-glycans on γδ T cells acts as a peripheral signal that amplifies a type 3/IL-17A response in ...

CAR-T cell therapy, approved for some blood cancers, is being studied for lupus, MS, and scleroderma. Yale Medicine experts ...